Stockscreener 앱 받기
16.49
2.55%
0.41
시간 외 거래:
16.49
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
Europe’s US-Listed ADRs Slipped Late Tuesday Morning - Finimize
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - markets.businessinsider.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV Technologies (NASDAQ: DBVT) targets Q3 2026 for VIASKIN Peanut BLA filing - Stock Titan
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing - The Manila Times
European ADRs Rose As Biopharma Names Led The Pack - Finimize
A40WEX Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
European ADRs Rose In US Trading Late Thursday Morning - Finimize
DBV1 Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index - markets.businessinsider.com
DBV Technologies S.A. - Via Ritzau
DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant Trial - Yahoo Finance
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
DBV Technologies Screens First Infant in THRIVE Peanut Patch Trial - HCPLive
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 - The Manila Times
Peanut patch helps allergic kids with asthma and eczema in trial - Stock Titan
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
European ADRs Slip As Nokia And Sequans Lead Declines - Finimize
DBV Technologies (NASDAQ: DBVT) ties 4,060,000 CEO PSUs to FDA milestones - Stock Titan
DBV Technologies Shareholders Approve Governance and Capital Measures - The Globe and Mail
DBV's Moment of Truth: A Patch, a Promise, and a High-Stakes Pitch - BriefGlance
DBV Technologies Announces the Results of its 2026 Combined General Meeting - markets.businessinsider.com
symbol__ Stock Quote Price and Forecast - CNN
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy - The Manila Times
DBV Technologies Announces First Participant Screened in - GlobeNewswire
Peanut-allergic babies enter THRIVE study for skin patch therapy - Stock Titan
European ADRs Tick Higher In US Trading - Finimize
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and TG Therapeutics (TGTX) - The Globe and Mail
DBVTDBV Technologies ADR Stock Price and Quote - Finviz
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
Combined General Meeting of June 3, 2026 - Moomoo
European ADRs Rose Monday, With Biotech Names Leading Moves - Finimize
MPM BioImpact reports 8.8% stake in DBV Technologies (DBVT) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Adage insiders report 22,272,884 shares in DBV Technologies (NASDAQ: DBVT) - Stock Titan
Artisan Partners (DBVT) discloses 2,219,386 ADS; 3.7% stake reported - Stock Titan
Vivo Opportunity (DBVT) holds 2.36M ADSs — 4.0% ownership disclosed - Stock Titan
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq - markets.businessinsider.com
2.64%
자본화:
|
볼륨(24시간):